Investor Presentaiton

Re-establishing Neuroscience pipeline 川 Neuroscience Anti-MTBR-Tau elF2B Activator ☐ Δ Building a diverse pipeline across an array of neurodegenerative & neuroinflammation diseases Anti-MTBR-Tau moving into POC next year in Alzheimer's Disease elF2B is moving into a Phase 2 trial in ALS Ill Bristol Myers Squibb™ TYK2i-CNS to transition into clinic soon targeting Multiple Sclerosis Not for Product Promotional Use 131

View entire presentation